FindTrial
Sign In

Pharmacogenomic research in anti-thyroid drugs-induced liver injury

Identification of susceptible gene loci and functional study in anti-thyroid drugs-induced liver injury

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018388
Enrollment
Unknown
Registered
2018-09-14
Start date
2017-11-01
Completion date
Unknown
Last updated
2018-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug-induced Liver Injury

Interventions

DILI:Methimazole
Control:methimazole

Sponsors

Department of endocrinology, Minhang Affiliated Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. serum AST or ALT >5×ULN on two separate occasions; 2. serum ALP >2× ULN on two consecutive occasions, or 3. serum total bilirubin > 2.4 mg/dL in the absence of a competing cause of hyperbilirubinemia.

Exclusion criteria

Exclusion criteria: Patients with a history of bone marrow or liver transplant prior to DILI onset or if there was a prior history of immune-related liver disease such as autoimmune hepatitis.

Design outcomes

Primary

MeasureTime frame
total bilirubin;alanine aminotransferase;alkaline phosphatase;aspartate aminotransferase;HLA Genotype;—

Secondary

MeasureTime frame
direct Bilirubin;—

Countries

China

Contacts

Public ContactYANG Jia-lin

Department of endocrinology, Minhang Affiliated Hospital, Fudan University

jialinyang2002@163.com+86 18918169025

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026